Drug Trial Radar · NCT03657030
Study of CVN424 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Sep 18, 2018
Primary completion
Mar 1, 2019
Study completion May 30, 2019
Sponsor
- Lead sponsor
- Cerevance Beta, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 4, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose ascending study in healthy subjects.
Conditions
- Healthy
Interventions
CVN424Drug
SAD / MAD
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of adverse eventsTime frame: Baseline through 14 days post-dose
- Evaluation of HematologyTime frame: Baseline through 14 days post-dose
- Evaluation of Vital SignsTime frame: Baseline through 14 days post-dose
- Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
- Evaluation of BMITime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
- Evaluation of Vital SignsTime frame: Baseline through 14 days post-dose
- Evaluation of Vital SignsTime frame: Baseline through 14 days post-dose
- Evaluation of Vital SignsTime frame: Baseline through 14 days post-dose
- Evaluation of HematologyTime frame: Baseline through 14 days post-dose
- Evaluation of HematologyTime frame: Baseline through 14 days post-dose
- Evaluation of HematologyTime frame: Baseline through 14 days post-dose
- Evaluation of HematologyTime frame: Baseline through 14 days post-dose
- Evaluation of HematologyTime frame: Baseline through 14 days post-dose
- Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
- Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
- Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
- Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
- Evaluation of ElectrocardiogramsTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of Serum ChemistryTime frame: Baseline through 14 days post-dose
- Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
- Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
- Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
- Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
- Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
- Evaluation of UrinalysisTime frame: Baseline through 14 days post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Development, LP
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.